MARKET

EVMN

EVMN

EVOMMUNE INC
NYSE
15.86
-1.77
-10.04%
After Hours: 15.85 -0.01 -0.06% 17:58 12/16 EST
OPEN
17.83
PREV CLOSE
17.63
HIGH
18.42
LOW
15.78
VOLUME
227.87K
TURNOVER
--
52 WEEK HIGH
24.03
52 WEEK LOW
15.78
MARKET CAP
499.97M
P/E (TTM)
-16.9626
1D
5D
1M
3M
1Y
5Y
1D
Buy Rating for Evommune, Inc. Driven by EVO756’s Promising Phase II Trial Potential
TipRanks · 1d ago
Weekly Report: what happened at EVMN last week (1208-1212)?
Weekly Report · 1d ago
Evommune (EVMN) Q3: Revenue Jump Reinforces Bullish Growth Narrative Despite Ongoing Losses
Simply Wall St · 3d ago
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Evommune, Inc. (EVMN) and Eli Lilly & Co (LLY)
TipRanks · 4d ago
Evommune, Inc.: Promising Pipeline and Strategic Trials Drive Buy Rating
TipRanks · 4d ago
Closing Bell Movers: Broadcom down 5%, Lululemon gains 10%
TipRanks · 5d ago
Evommune, Inc. GAAP EPS of -$8.07, revenue of $10M
Seeking Alpha · 5d ago
*Evommune 3Q Rev $10M Vs. / >EVMN
Dow Jones · 5d ago
More
About EVMN
Evommune, Inc. is a clinical-stage biotechnology company developing therapies that target key drivers of chronic inflammatory diseases. Its initial clinical development programs are focusing on chronic spontaneous urticaria (CSU), atopic dermatitis (AD) and ulcerative colitis (UC). Its product candidates include EVO756 and EVO301. The Company's advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons, which is initially being evaluated in Phase II trials for the treatment of CSU and AD. The Company's second clinical-stage product candidate, EVO301, is a long-acting fusion protein consisting of an IL-18 binding protein (BP) and an anti-serum albumin Fab-associated (SAFA) domain, which is being evaluated in Phase II trials for the treatment of AD and UC.

Webull offers Evommune, Inc. stock information, including NYSE: EVMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVMN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EVMN stock methods without spending real money on the virtual paper trading platform.